Literature DB >> 30108698

Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase.

Ibrahim M El-Deeb1, Patrice Guillon1, Larissa Dirr1, Mark von Itzstein1.   

Abstract

Human parainfluenza virus type-3 is a leading cause of acute respiratory infection in infants and children. There is currently neither vaccine nor clinically effective treatment for parainfluenza virus infection. Hemagglutinin-neuraminidase glycoprotein is a key protein in viral infection, and its inhibition has been a target for inhibitor development. In this study, we explore the structural features required for Neu2en derivatives to efficiently lock-open the 216-loop of the human parainfluenza virus type-3 hemagglutinin-neuraminidase protein.

Entities:  

Year:  2016        PMID： 30108698      PMCID： PMC6072455          DOI： 10.1039/c6md00519e

Source DB:  PubMed          Journal:  Medchemcomm        ISSN： 2040-2503            Impact factor:   3.597


  17 in total

1.  Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Authors:  Makiko Watanabe; Vasiliy P Mishin; Scott A Brown; Charles J Russell; Kelli Boyd; Y Sudhakara Babu; Garry Taylor; Xiaoping Xiong; Xiaowei Yan; Allen Portner; Irina V Alymova
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 2.  From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses.

Authors:  C A Heilman
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

3.  Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.

Authors:  Deju Ye; Woo-Jin Shin; Ning Li; Wei Tang; Enguang Feng; Jian Li; Pei-Lan He; Jian-Ping Zuo; Hanjo Kim; Ky-Youb Nam; Weiliang Zhu; Baik-Lin Seong; Kyoung Tai No; Hualiang Jiang; Hong Liu
Journal:  Eur J Med Chem       Date:  2012-06-29       Impact factor: 6.514

4.  Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population.

Authors:  K J Cortez; D D Erdman; T C Peret; V J Gill; R Childs; A J Barrett; J E Bennett
Journal:  J Infect Dis       Date:  2001-10-12       Impact factor: 5.226

5.  The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed.

Authors:  Larissa Dirr; Ibrahim M El-Deeb; Patrice Guillon; Cindy J Carroux; Leonard M G Chavas; Mark von Itzstein
Journal:  Angew Chem Int Ed Engl       Date:  2015-02-10       Impact factor: 15.336

6.  Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.

Authors:  Irina V Alymova; Garry Taylor; Toru Takimoto; Tsu-Hsing Lin; Pooran Chand; Y Sudhakara Babu; Chenghong Li; Xiaoping Xiong; Allen Portner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.

Authors:  K Huberman; R W Peluso; A Moscona
Journal:  Virology       Date:  1995-12-01       Impact factor: 3.616

8.  Exploring human parainfluenza virus type-1 hemagglutinin-neuraminidase as a target for inhibitor discovery.

Authors:  Ibrahim M El-Deeb; Patrice Guillon; Moritz Winger; Tanguy Eveno; Thomas Haselhorst; Jeffrey C Dyason; Mark von Itzstein
Journal:  J Med Chem       Date:  2014-09-08       Impact factor: 7.446

9.  A dual drug regimen synergistically blocks human parainfluenza virus infection.

Authors:  Benjamin Bailly; Larissa Dirr; Ibrahim M El-Deeb; Ralf Altmeyer; Patrice Guillon; Mark von Itzstein
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

Review 10.  The cell biology of acute childhood respiratory disease: therapeutic implications.

Authors:  Gerald M Loughlin; Anne Moscona
Journal:  Pediatr Clin North Am       Date:  2006-10       Impact factor: 3.278
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.